YOLFTbeta
Equillium Inc

Equillium Inc

EQ · NASDAQ · Healthcare / Biotechnology

1.29USD-0.03 (-2.27%)

Price History

Full chart

Market Stats

Previous Close1.32
Open1.36
Day Range1.27 – 1.36
52-Week Range0.7562 – 3.54
Volume468.85K
Market Cap105.89M
P/E (TTM)0.00
Forward P/E1.53
EPS-0.09
Dividend Yield0.00%
Beta1.80
50-Day Avg2.25
200-Day Avg2.06

About

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Bruce Steel
  • Employees14
  • Headquarters2223 Avenida De La Playa, La Jolla, CA, United States, 92037, USA
  • Websitehttps://www.equilliumbio.com

Leadership

  • Mr. Bruce SteelCo-Founder, CEO & Director · b. 1966
  • Dr. Stephen Connelly Ph.D.Chief Scientific Officer & President · b. 1981
  • Ms. Christine Zedelmayer M.B.A., P.M.P.Senior VP & COO · b. 1970
  • Ms. Penny Tom CPASenior VP of Finance & Principal Accounting Officer
  • Mr. Michael MooreVice President of Investor Relations & Corporate Communications
  • Ms. Snehal Naik Ph.D.Chief Development Officer
  • Dr. Lisette AcevedoVice President of Clinical Development

Financials

Income Statement

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue0000015.76M36.08M41.09M130.00K
Growth (%)------+128.97%+13.89%-99.68%
Cost of Revenue1226.10K23.00K45.00K72.00K118.00K126.00K137.00K116.00K
Gross Profit-122-6.10K-23.00K-45.00K-72.00K15.76M36.08M41.09M-116.00K
Gross Margin-----100.00%100.00%100.00%-89.23%
Operating Expense1.71M8.61M26.70M29.50M37.71M77.83M50.61M49.36M23.52M
Operating Income-1.71M-8.62M-26.73M-29.55M-37.79M-62.08M-14.52M-8.27M-23.63M
Operating Margin------393.91%-40.24%-20.12%-18180.00%
EBITDA-1.88M-8.61M-26.70M-29.50M-37.71M-61.26M-12.14M-7.57M-22.28M
EBITDA Margin------388.71%-33.64%-18.42%-17140.00%
Net Income-2.26M-13.25M-25.58M-29.77M-38.98M-62.43M-13.34M-8.07M-22.40M
Net Income Margin------396.14%-36.96%-19.63%-17229.23%
R&D1.33M4.94M17.64M19.38M26.38M37.55M37.04M37.43M12.84M
R&D as % of Total Revenue-----238.26%102.65%91.08%9879.23%
Interest Expense379.38K2.56M279.00K1.10M1.07M1.05M491.00K0-
Interest Expense % of Total Revenue-----6.68%1.36%0.00%-

Balance Sheet

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets7.15M67.16M55.54M85.43M85.41M78.42M50.53M25.60M31.89M
Total Liabilities9.40M2.23M13.69M15.57M18.90M46.48M27.96M6.54M3.29M
Total Equity-2.25M64.94M41.85M69.85M66.50M31.94M22.57M19.06M28.60M
Cash7.10M28.51M13.22M23.98M50.37M59.11M23.22M18.09M30.28M
Total Debt16.12M200.00K9.68M9.94M10.55M10.19M824.00K384.00K719.00K
Net Debt955.31K-28.31M-3.54M-15.71M-40.38M-48.92M-22.39M-17.70M-29.56M

Cash Flow

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-662.20K-7.53M-22.95M-24.62M-32.08M-8.73M-21.78M-19.03M-22.75M
Investing Cash Flow-2.20K-37.43M-2.17M-18.59M27.41M18.68M-4.76M13.81M4.46M
Financing Cash Flow7.77M66.37M9.84M53.95M31.06M-1.22M-9.23M164.00K30.43M
Capital Expenditure2.20K34.86K74.00K202.00K57.00K279.00K50.00K85.00K48.00K
Free Cash Flow-664.40K-7.56M-23.02M-24.83M-32.14M-9.01M-21.83M-19.11M-22.79M
Dividends Paid--9.88M---9.13M--
FCF to OCF100.33%100.46%100.32%100.82%100.18%103.19%100.23%100.45%100.21%
Dividend Paid to FCF---42.92%----41.83%--

Earnings

Report DateAug 3, 2018Nov 15, 2018Mar 27, 2019May 13, 2019Aug 12, 2019Nov 12, 2019Mar 26, 2020May 13, 2020Aug 12, 2020Nov 10, 2020Mar 24, 2021May 13, 2021Aug 10, 2021Nov 10, 2021Mar 23, 2022May 12, 2022Aug 15, 2022Nov 14, 2022Mar 23, 2023May 11, 2023Aug 9, 2023Nov 8, 2023Mar 25, 2024May 9, 2024Aug 8, 2024Nov 13, 2024Mar 27, 2025May 14, 2025Aug 14, 2025Nov 13, 2025Mar 26, 2026May 13, 2026Aug 13, 2026Nov 12, 2026
EPS Estimate0.00-0.11-0.29-0.30-0.41-0.42-0.39-0.41-0.44-0.44-0.40-0.32-0.32-0.34-0.34-0.38-0.40-0.37-0.03-0.06-0.11-0.12-0.17-0.11-0.130.14-0.31-0.33-0.18-0.22-0.07-0.04-0.05-0.05
EPS Actual-0.14-0.31-0.31-0.34-0.35-0.35-0.44-0.45-0.37-0.31-0.36-0.33-0.31-0.35-0.36-1.17-0.41-0.400.08-0.11-0.10-0.11-0.07-0.080.01-0.00-0.16-0.24-0.16-0.06-0.04-0.06-0.04-
Surprise--181.82%-6.90%-13.33%14.63%16.67%-12.82%-9.76%15.91%29.55%10.00%-3.13%3.13%-2.94%-5.88%-207.89%-2.50%-8.11%366.67%-83.33%9.09%8.33%58.82%27.27%107.69%-100.14%48.39%27.27%11.11%72.73%42.86%-50.00%20.00%-
Timing-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap105.89M
Enterprise Value54.38M
Trailing P/E0.00
Forward P/E1.53
Price / Sales20.22
Price / Book2.18
EPS-0.09
Book Value0.883
Revenue (TTM)4.39M
Gross Profit (TTM)4.39M
EBITDA-19.20M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-58.98%
Return on Assets-33.95%
Shares Outstanding63.41M
Shares Float36.97M
Beta1.80
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Hold
Based on 2 analystsTarget 8.56
  • Hold
    2

Ownership Breakdown

Institutions
65.82%
Insiders
16.00%
Retail / Other
18.18%

Top Institutional Holders

  • HHG PLC
    6.49M10.24%
  • Decheng Capital LLC
    4.45M7.01%
  • Affinity Asset Advisors, LLC
    4.10M6.47%
  • ADAR1 Capital Management LLC
    3.73M5.88%
  • Aberdeen Group PLC
    3.63M5.73%
  • Woodline Partners LP
    3.50M5.52%
  • RA Capital Management, LLC
    3.10M4.88%
  • Vanguard Capital Management, LLC
    1.78M2.81%
  • Balyasny Asset Management LLC
    1.64M2.58%
  • Eversept Partners, LP
    1.52M2.40%
  • Adage Capital Partners Gp LLC
    1.39M2.19%
  • Renaissance Technologies Corp
    656.96K1.04%
  • Exome Asset Management LLC
    552.96K0.87%
  • DG Capital Management, LLC
    463.40K0.73%
  • Diadema Partners LP
    400.28K0.63%
  • Geode Capital Management, LLC
    378.81K0.60%
  • Tudor Investment Corp Et AL
    320.10K0.50%
  • Ikarian Capital, LLC
    303.56K0.48%

Top Fund Holders

  • abrdn Life Sciences Investors
    3.71M5.85%
  • Vanguard MStar Total Stk Mkt Idx Invest
    1.40M2.21%